Abstract
In only two years, the coronavirus disease 2019 (COVID-19) pandemic has had a devastating effect on public health all over the world and caused irreparable economic damage across all countries. Due to the limited therapeutic management of COVID-19 and the lack of tailor-made antiviral agents, finding new methods to combat this viral illness is now a priority. Herein, we report on a specific oligonucleotide-based RNA inhibitor targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It displayed remarkable spontaneous cellular uptake, >94% efficiency in reducing RNA-dependent RNA polymerase (RdRp) RNA levels in transfected lung cell lines, and >98% efficiency in reducing SARS-CoV-2 RNA levels in samples from patients hospitalized with COVID-19 following a single application.
Keywords: COVID-19; RNA levels; RdRp; SARS-CoV-2; oligonucleotide-based RNA inhibitor.
【저자키워드】 COVID-19, SARS-CoV-2, RdRP, RNA levels, oligonucleotide-based RNA inhibitor., 【초록키워드】 coronavirus disease, public health, Coronavirus disease 2019, coronavirus, pandemic, severe acute respiratory syndrome Coronavirus, RNA, management, Antiviral agents, therapeutic, RdRP, RNA-dependent RNA polymerase, SARS-CoV-2 RNA, inhibitor, cellular, Efficiency, acute respiratory syndrome, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, priority, lung cell lines, oligonucleotide, lack, caused, reducing, patients hospitalized, with COVID-19, 【제목키워드】 RNA, SARS-CoV-2 RNA, Level,